Caihua Qian, Jingting Liu, Chunyan Meng, Jun Cheng, Bo Wu, Jianhua Liao
{"title":"消化系统癌症中血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分的显著预后价值：一项系统综述和荟萃分析。","authors":"Caihua Qian, Jingting Liu, Chunyan Meng, Jun Cheng, Bo Wu, Jianhua Liao","doi":"10.1186/s12885-025-15068-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Digestive system cancers are a major global health burden, necessitating reliable and cost-effective prognostic biomarkers for clinical decision-making. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, an integrated immune-nutrition marker, has emerged as a potential prognostic tool in various malignancies. This meta-analysis evaluated the prognostic value of the HALP score in patients with digestive system cancers.</p><p><strong>Methods: </strong>A systematic search was performed in PubMed, PMC, and Web of Science database for studies assessing HALP scores calculated from pre-treatment blood tests and reporting survival outcomes in patients with digestive system cancers. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of the HALP score.</p><p><strong>Results: </strong>A total of 30 articles comprising 34 studies and 9,389 patients were included. High HALP scores were significantly associated with improved survival outcomes. The pooled HR for overall survival (OS) was 1.762 (95% CI: 1.570-1.977, P < 0.001), and similar results were found for disease-free survival (DFS) (HR = 1.841, 95% CI: 1.311-2.585, P < 0.001), recurrence-free survival (RFS) (HR = 1.583, 95% CI: 1.374-1.824, P < 0.001), cancer-specific survival (CSS) (HR = 1.930, 95% CI: 1.590-2.341, P < 0.001), and progression-free survival (PFS) (HR = 1.444, 95% CI: 1.068-1.954, P = 0.017). Subgroup analyses confirmed the robustness of these findings across different treatment strategies and cancer types. Sensitivity and bias analyses (P = 0.103) supported the reliability of these results.</p><p><strong>Conclusion: </strong>The HALP score is a promising prognostic biomarker for digestive system cancers, offering potential for clinical application in personalizing treatment strategies. Future studies should aim to standardize methodologies and validate HALP in prospective multicenter trials.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1577"},"PeriodicalIF":3.4000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523103/pdf/","citationCount":"0","resultStr":"{\"title\":\"The significant prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in digestive system cancers: a systematic review and meta-analysis.\",\"authors\":\"Caihua Qian, Jingting Liu, Chunyan Meng, Jun Cheng, Bo Wu, Jianhua Liao\",\"doi\":\"10.1186/s12885-025-15068-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Digestive system cancers are a major global health burden, necessitating reliable and cost-effective prognostic biomarkers for clinical decision-making. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, an integrated immune-nutrition marker, has emerged as a potential prognostic tool in various malignancies. This meta-analysis evaluated the prognostic value of the HALP score in patients with digestive system cancers.</p><p><strong>Methods: </strong>A systematic search was performed in PubMed, PMC, and Web of Science database for studies assessing HALP scores calculated from pre-treatment blood tests and reporting survival outcomes in patients with digestive system cancers. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of the HALP score.</p><p><strong>Results: </strong>A total of 30 articles comprising 34 studies and 9,389 patients were included. High HALP scores were significantly associated with improved survival outcomes. The pooled HR for overall survival (OS) was 1.762 (95% CI: 1.570-1.977, P < 0.001), and similar results were found for disease-free survival (DFS) (HR = 1.841, 95% CI: 1.311-2.585, P < 0.001), recurrence-free survival (RFS) (HR = 1.583, 95% CI: 1.374-1.824, P < 0.001), cancer-specific survival (CSS) (HR = 1.930, 95% CI: 1.590-2.341, P < 0.001), and progression-free survival (PFS) (HR = 1.444, 95% CI: 1.068-1.954, P = 0.017). Subgroup analyses confirmed the robustness of these findings across different treatment strategies and cancer types. Sensitivity and bias analyses (P = 0.103) supported the reliability of these results.</p><p><strong>Conclusion: </strong>The HALP score is a promising prognostic biomarker for digestive system cancers, offering potential for clinical application in personalizing treatment strategies. Future studies should aim to standardize methodologies and validate HALP in prospective multicenter trials.</p>\",\"PeriodicalId\":9131,\"journal\":{\"name\":\"BMC Cancer\",\"volume\":\"25 1\",\"pages\":\"1577\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523103/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12885-025-15068-x\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-15068-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：消化系统癌症是全球主要的健康负担，需要可靠且具有成本效益的预后生物标志物用于临床决策。血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分是一种综合免疫营养标志物，已成为各种恶性肿瘤的潜在预后工具。本荟萃分析评估了HALP评分在消化系统癌症患者中的预后价值。方法：在PubMed， PMC和Web of Science数据库中进行系统搜索，以评估从治疗前血液检查计算的HALP评分和报告消化系统癌症患者生存结果的研究。合并风险比（hr）和95%置信区间（ci）来评估HALP评分的预后意义。结果：共纳入30篇文章，34项研究，9389例患者。高HALP评分与改善的生存结果显著相关。总生存期（OS）的合并HR为1.762 （95% CI: 1.570-1.977， P）结论：HALP评分是一种很有希望的消化系统癌症预后生物标志物，为个性化治疗策略的临床应用提供了潜力。未来的研究应旨在标准化方法，并在前瞻性多中心试验中验证HALP。
The significant prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in digestive system cancers: a systematic review and meta-analysis.
Background: Digestive system cancers are a major global health burden, necessitating reliable and cost-effective prognostic biomarkers for clinical decision-making. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, an integrated immune-nutrition marker, has emerged as a potential prognostic tool in various malignancies. This meta-analysis evaluated the prognostic value of the HALP score in patients with digestive system cancers.
Methods: A systematic search was performed in PubMed, PMC, and Web of Science database for studies assessing HALP scores calculated from pre-treatment blood tests and reporting survival outcomes in patients with digestive system cancers. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of the HALP score.
Results: A total of 30 articles comprising 34 studies and 9,389 patients were included. High HALP scores were significantly associated with improved survival outcomes. The pooled HR for overall survival (OS) was 1.762 (95% CI: 1.570-1.977, P < 0.001), and similar results were found for disease-free survival (DFS) (HR = 1.841, 95% CI: 1.311-2.585, P < 0.001), recurrence-free survival (RFS) (HR = 1.583, 95% CI: 1.374-1.824, P < 0.001), cancer-specific survival (CSS) (HR = 1.930, 95% CI: 1.590-2.341, P < 0.001), and progression-free survival (PFS) (HR = 1.444, 95% CI: 1.068-1.954, P = 0.017). Subgroup analyses confirmed the robustness of these findings across different treatment strategies and cancer types. Sensitivity and bias analyses (P = 0.103) supported the reliability of these results.
Conclusion: The HALP score is a promising prognostic biomarker for digestive system cancers, offering potential for clinical application in personalizing treatment strategies. Future studies should aim to standardize methodologies and validate HALP in prospective multicenter trials.
期刊介绍：
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
